Tumor motion is a significant factor inhibiting targeting accuracy in radiation therapy. The development of X-ray volume imaging (XVI) and its suite of imaging tools was driven by the need to visualize internal structures, within the reference frame of the treatment system, to reduce geometric uncertainties. The ability to image at the time of treatment with the patient in the treatment position reduces issues relating to organ movement and inspires clinical confidence to pursue advanced delivery techniques.
XVI imaging technology
Planning and treating in 3D requires verification in 3D. The 3D imaging capability of XVI enables clinicians to take full advantage of complex techniques without the need for implanted markers to visualize soft tissue structures, target volume and the position of critical structures.
It allows precise registration of the reconstructed image data with the historical CT planning data as a non-invasive procedure. XVI offers a variety of image guided options to suit the individual needs of the patient and the clinic XVI software offers the flexibility to vary the dosage necessary to acquire a VolumeView image, depending on the level of contrast required.
Working closely with the Elekta Synergy Research Group, Elekta, in collaboration with its clinical partners, became the first company to support research on IGRT, the first to bring 3D volumetric imaging into clinical use and the first to bring these solutions to the wider market.
Key advantages offered by VolumeView imaging at the time of treatment include:
Versatile, all in one system from classic radiotherapy to advanced stereotactic precision.
Elekta’s most advanced linear accelerator capable of delivering exquisite dose conformance for an expanded range of targets, plus ground-breaking innovations designed to improve efficiency. Ideal for stereotactic treatment techniques.
At the forefront of clinical advancements, Elekta has been instrumental in delivering techniques like IGRT, IMRT, VMAT as well as SBRT and SRT. These techniques have given clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.